Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks
Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
Start Today
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

Merck & Company (MRK-N) Quote

Register
AdChoices
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 78.28
Day High 78.28
Open:78.28
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Latest
inside the market
Market movers: Stocks that saw action on Tuesday - and why
Subscriber content
international business
Merck to buy Austrian vaccine maker as it jumps into COVID-19 race
Subscriber content
investment ideas
Investors prepare for more U.S. stock swings as states reopen
top links
Goldman’s top U.S. dividend stock picks with healthy balance sheets, reasonable payout ratios
Subscriber content
inside the market
Market movers: Stocks that saw action on Tuesday - and why
Subscriber content
investment ideas
Spotlight falls on ‘dividend aristocrats’ after market tumult
Description
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings zacks

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

View Estimates zacks

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Download Report (PDF) Thomson Reuters

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Download Report (PDF) StockCalc

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Download Report (PDF) ValueEngine logo

Latest Press Releases

More Stories
RefleXion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy With Merck's KEYTRUDA(R) for Certain Late-Stage Cancers
- BusinessWire - 7 minutes ago
BusinessWire - CMTX
7 minutes ago
RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) for treating all stages of cancer, today announced a clinical collaboration with Merck (known as MSD outside the U.S. and Canada) to evaluate the safety and efficacy of KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy, in combination with BgRT in multiple late-stage cancers, including non-small cell lung cancer (NSCLC), in two randomized controlled clinical trials.
Insights on the Worldwide Stable Isotope Labeled Compounds Industry to 2025 - Featuring PerkinElmer, Merck & 3M Among Others - ResearchAndMarkets.com
- BusinessWire - 10 minutes ago
BusinessWire - CMTX
10 minutes ago
The "Global Stable Isotope Labeled Compounds Market, By Compounds (Carbon (13C), Nitrogen(15N), Deuterium, Oxygen(18O), Others), By Application, By Substances, By Indication, By Method, By End-User, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.
Insights on the Worldwide Peptide Synthesis Industry to 2025 - Featuring Genscript Biotech, Merck & Pepscan Among Others
- GlobeNewswire - Thu May 28, 5:38AM CDT
GlobeNewswire - CMTX
Thu May 28, 5:38AM CDT
The "Global Peptide Synthesis Market By Application (Epitope-specific antibodies, Epitope mapping, Others), By Type, By Technology, By Product, By Type of Resin, By Labelling, By End-User, By Region, Competition, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 75.43 +3.78% increase
on 05/07/20
Period Open:81.18
Price movement based on the high, low and last over the given period.
82.19 -4.76% decrease
on 04/29/20
 -2.90 (-3.57%) decrease
since 04/28/20
3-Month 65.25 +19.97% increase
on 03/23/20
Period Open:76.56
Price movement based on the high, low and last over the given period.
84.67 -7.55% decrease
on 04/27/20
 +1.72 (+2.25%) increase
since 02/28/20
52-Week 65.25 +19.97% increase
on 03/23/20
Period Open:80.26
Price movement based on the high, low and last over the given period.
92.64 -15.50% decrease
on 12/20/19
 -1.98 (-2.47%) decrease
since 05/28/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies